Francesco Pierantoni

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna et al. · Therapeutic Advances in Medical Oncology · 2021 · 86 citations · Full text

Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial

Francesca Vignani, Rosa Tambaro, Ugo De Giorgi et al. · European Urology · 2022 · 20 citations

Urology, Genitourinary Cancer, Maintenance Treatment +6

Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience

Francesco Pierantoni, Umberto Basso, Marco Maruzzo et al. · Journal of Geriatric Oncology · 2020 · 18 citations

Geriatric Oncology, Urology, Genitourinary Cancer +10

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)

Marco Stellato, Sebastiano Buti, Marco Maruzzo et al. · International Journal of Molecular Sciences · 2023 · 16 citations · Full text

Renal Pathology, Papillary Histology, Pathology +20

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations

Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou et al. · Minerva Urology and Nephrology · 2023 · 15 citations · Full text